Press Releases

Press Releases

March 28, 2017
CAMBRIDGE, Mass., March 28, 2017 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced three additions to the company's board of directors: Christopher Gabrieli, partner emeritus of Bessemer Venture Partners. Mr.
March 27, 2017
CAMBRIDGE, Mass., March 27, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.
March 6, 2017
77% Mean Triglyceride Reduction in Patients with FCS Reductions in Pancreatitis Events and Abdominal Pain Webcast to Discuss Results March 6, 2017 at 8:30 am ET CARLSBAD, Calif. and CAMBRIDGE, Mass. , March 6, 2017 /PRNewswire/ -- Akcea Therapeutics, a wholly owned subsidiary of Ionis
February 16, 2017
 Ionis and Akcea to receive $75 million up-front payment - Deal valued at more than $1 billion   CARLSBAD, Calif. and CAMBRIDGE, Mass., Feb. 16, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Akcea Therapeutics, a wholly-owned subsidiary
January 6, 2017
- Collaboration with Novartis provides near-term payments of $225 million plus potential license fees, milestone and royalty payments - Akcea retains rights to co-commercialize to lipid specialists - Deal valued at significantly over $1 billion if both drugs are licensed and successfully
December 19, 2016
71% Mean Triglyceride Reduction in Patients with Severe Hypertriglyceridemia 73% Mean Triglyceride Reduction in Patients with FCS   CARLSBAD, Calif. and CAMBRIDGE, Mass., Dec. 19, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Ionis
November 15, 2016
Significant reductions in ANGPTL3, triglycerides and LDL cholesterol observed Interim data presented during the Late Breaker Session at the American Heart Association Meeting   CAMBRIDGE, Mass., Nov. 15, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary
September 22, 2016
CAMBRIDGE, Mass., Sept. 22, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the publication in  The Lancet  of key clinical results of two randomized, controlled studies of
September 15, 2016
--Largest study conducted to date involving people living with FCS-- --Findings to be presented during American Society for Preventative Cardiology Congress-- CAMBRIDGE, Mass. , Sept. 15, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Ionis
July 28, 2016
CAMBRIDGE, Mass., July 28, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the European Commission (EC) has designated volanesorsen as an orphan medicinal product for the